Merck

Merck held talks to buy biotech MoonLake for over US billion: FT
Merck held talks to buy biotech MoonLake for over US$3 billion: FT
June 2, 2025
Published Tue, Jun 3, 2025 · 07:45 AMMERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times reported on Monday, citing...
China’s WuXi Biologics to sell vaccine facility to Merck for US0 million
China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million
January 7, 2025
WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks to enhance its margins while continuing to navigate...
Merck snags Chinese obesity drug in nearly US billion deal
Merck snags Chinese obesity drug in nearly US$2 billion deal
December 19, 2024
MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion.Under the terms of the deal, the company will...
Merck snags Chinese cancer drug for up to US.3 billion
Merck snags Chinese cancer drug for up to US$3.3 billion
November 14, 2024
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million upfront, plus as much as US$2.7 billion in milestone...
China’s WuXi Biologics to sell vaccine facility to Merck for US0 million
Merck narrows sales outlook with Gardasil lagging in China
October 31, 2024
MERCK lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter in China. Sales of the Gardasil shot, which...
Germany’s Merck open to more M&A for its Life Science division
Germany’s Merck open to more M&A for its Life Science division
October 17, 2024
GERMAN science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for US$600 million, it...
Merck cuts annual profit forecast
Merck cuts annual profit forecast
July 30, 2024
Merck on Tuesday (Jul 30) cut its full-year earnings forecast, mainly due to one-time charges from its acquisition of eye-focused drug developer EyeBio.Merck now expects 2024 earnings of US$7.94...